Community Practice Grand Rounds: Experts Explore the Latest Evidence and Guideline Updates in Chronic Lymphocytic Leukemia

Improve your practice in selecting the appropriate first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and integrating novel combinations that include noncovalent BTK inhibitors and CAR T-cell therapy across the disease spectrum. All of which can be done by developing individualized patient treatment plans, with tangible strategies shared in an on-demand webcast, downloadable slides, and an expert-written ClinicalThought commentary.

Share

Program Content

Activities

Latest Evidence and Guideline Updates in CLL
Community Practice Grand Rounds: Experts Explore the Latest Evidence and Guideline Updates in Chronic Lymphocytic Leukemia
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 21, 2025

Expires: January 20, 2026

Faculty

cover img faculity

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

cover img faculity

Jennifer R. Brown, MD, PhD

Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Harvard Medical School
CLL Center Director and Institute Physician
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

Supporters

This activity is supported by educational grants from AstraZeneca and Lilly. This activity is supported by an independent medical education grant from AbbVie.

AbbVie

AstraZeneca

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner